RxDoctor Payments Data

George Budd, MD

Medical Oncology · Cleveland, OHNPI 1457315673

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 37.8% of the total.

$21,513in general payments, 2019–2025

Across 23 payments — averaging $935.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$8K
  • Gilead$4K
  • Aadi Bioscience, Inc.$4K
  • Pfizer$3K
  • Daiichi Sankyo Inc.$2K
  • Genentech, Inc.$750
  • plus $166 from 1 others
$385,633in research payments, 2019–2025

Across 51 payments — averaging $7561.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$290K
  • Janssen Research & Development, LLC$43K
  • Daiichi Sankyo Inc.$26K
  • Pfizer$20K
  • Merck$7K
  • AstraZeneca$749

What the payments were for

  • Consulting fees$9,36844%
  • Speaking & faculty fees$11,49553%
  • Food & beverage$6383%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,513 in reported general payments places this provider in the 80th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$24,760
Medicare patients
125
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate15$445,581
KisqaliRibociclib Succinate30$430,465
TruqapCapivasertib12$278,921
Imatinib Mesylate39$47,630
Anastrozole71$1,485
Colestipol Hcl15$818
Ondansetron Hcl22$781
Letrozole30$573
Klor-Con M20Potassium Chloride11$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$166$430,46530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →